These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26692039)

  • 1. Iloprost treatment in pediatric patients with complicated Raynaud's phenomenon.
    Cekic S; Kilic SS
    Lupus; 2016 Apr; 25(5):558-60. PubMed ID: 26692039
    [No Abstract]   [Full Text] [Related]  

  • 2. Raynaud's Phenomenon.
    Wigley FM; Flavahan NA
    N Engl J Med; 2016 Aug; 375(6):556-65. PubMed ID: 27509103
    [No Abstract]   [Full Text] [Related]  

  • 3. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raynaud, digital ulcers and calcinosis in scleroderma.
    Nitsche A
    Reumatol Clin; 2012; 8(5):270-7. PubMed ID: 22835924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iloprost treatment for refractory Raynaud's phenomenon in two infants.
    Shouval DS; Mukamel M; Zulian F; Amir J; Harel L
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S105-7. PubMed ID: 18799065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon.
    Lamprecht P; Schnabel A; Gross WL
    Br J Rheumatol; 1998 Jun; 37(6):703-4. PubMed ID: 9667634
    [No Abstract]   [Full Text] [Related]  

  • 8. Raynaud's Syndrome: a neglected disease.
    Poredos P; Poredos P
    Int Angiol; 2016 Apr; 35(2):117-21. PubMed ID: 25673314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
    Cochrane Database Syst Rev; 2000; 1998(2):CD000953. PubMed ID: 10796395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases].
    García Hernández FJ; Ocaña Medina C; Mateos Romero L; Molinillo López J; Arias Zambrano A; González León R; Sánchez Román J
    Med Clin (Barc); 2004 Apr; 122(13):501-4. PubMed ID: 15104947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Iloprost for the treatment of systemic sclerosis].
    Hachulla E; Launay D; Hatron PY
    Presse Med; 2008 May; 37(5 Pt 2):831-9. PubMed ID: 18035518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.
    Caramaschi P; Martinelli N; Volpe A; Pieropan S; Tinazzi I; Patuzzo G; Mahamid H; Bambara LM; Biasi D
    Clin Rheumatol; 2009 Jul; 28(7):807-13. PubMed ID: 19301062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raynaud's phenomenon.
    Solomons HD
    Cardiovasc J Afr; 2011; 22(5):233. PubMed ID: 21983952
    [No Abstract]   [Full Text] [Related]  

  • 15. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Joint hypermobility syndrome and bilateral total occlusion of the ulnar arteries presenting as Raynaud's phenomenon.
    Haberhauer G; Feyertag J; Hanusch-Enserer U; Dunky A
    Clin Exp Rheumatol; 2000; 18(2):270-1. PubMed ID: 10812513
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of Raynaud's phenomenon].
    Lazareth I
    Ann Dermatol Venereol; 2001 Apr; 128(4):553-6. PubMed ID: 11395659
    [No Abstract]   [Full Text] [Related]  

  • 18. Raynaud's of the gut? Systemic sclerosis-associated microvascular ischaemic colitis responsive to intravenous iloprost.
    Pratap K; Penglase R; Roper E; Stoita A
    Rheumatology (Oxford); 2024 Aug; 63(8):e219-e221. PubMed ID: 38290764
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.
    Marasini B; Massarotti M; Bottasso B; Coppola R; Del Papa N; Maglione W; Comina DP; Maioli C
    Scand J Rheumatol; 2004; 33(4):253-6. PubMed ID: 15370722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion.
    McGrath SE; Webb A; Walker-Bone K
    J Clin Oncol; 2013 Feb; 31(4):e51-2. PubMed ID: 23270004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.